Oncorus Stock

oncorus.comHealthcareFounded: 2015Funding to Date: $140.5MM

Oncorus is a pre-clinical stage biotechnology company developing innovative and impactful, next-generation oncolytic HSV products with unprecedented potential to recruit all arms of immune system to treat solid tumors.

Register for Details

For more details on financing and valuation for Oncorus, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Oncorus.

Register Today

Team

Management Team

Christophe Quéva Ph.D
Chief Scientific Officer
Mitchell Finer Ph.D
Founder & Executive Chairman
Theodore Ashburn Ph.D
Chief Executive Officer, President and Board Member
Eric Sullivan
Senior Vice President, Finance & Operations, Treasurer
John McCabe
Chief Financial Officer

Board Members

Cameron Wheeler Ph.D
Deerfield Management
Luke Evnin Ph.D
MPM Capital
Spencer Nam
Alon Lazarus Ph.D
Mitchell Finer Ph.D
Briggs Morrison MD
MPM Capital
Robert Kirkman MD
Theodore Ashburn Ph.D

Other companies like Oncorus in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.67B
Sector
 
 
Sector
Last Round Est. Valuation
$317.32MM
Sector
Last Round Est. Valuation
$4.26B
Sector
Last Round Est. Valuation
$1.59B
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$334.19MM

News

Oncorus, Inc., a viral immunotherapies company, today announced the appointment of John McCabe as Chief Financial Officer.
Nearly four years ago, the FDA approved a therapy that uses a virus to infect tumor cells and break them down---the first such viral therapy for treating